Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy
- 6 May 2019
- journal article
- letter
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 60 (11), 2806-2809
- https://doi.org/10.1080/10428194.2019.1605068
Abstract
(2019). Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leukemia & Lymphoma. Ahead of Print.Keywords
This publication has 12 references indexed in Scilit:
- Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation SettingTransplantation and Cellular Therapy, 2018
- The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?British Journal of Dermatology, 2017
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialThe Lancet, 2017
- Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary SyndromeJournal of Neuro-Oncology, 2017
- Brentuximab Vedotin: A Review in CD30-Positive Hodgkin LymphomaDrugs, 2017
- Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaBlood, 2016
- The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseThe Oncologist, 2015
- Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative ProjectJournal of Clinical Oncology, 2015
- Brentuximab vedotin: axonal microtubule’s ApollyonBlood Cancer Journal, 2015
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2015